Perennial Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 6.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,436 shares of the medical research company’s stock after buying an additional 772 shares during the period. Thermo Fisher Scientific makes up about 1.7% of Perennial Advisors LLC’s investment portfolio, making the stock its 24th largest holding. Perennial Advisors LLC’s holdings in Thermo Fisher Scientific were worth $2,542,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Proficio Capital Partners LLC lifted its position in Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after purchasing an additional 253 shares during the period. Chicago Partners Investment Group LLC acquired a new stake in Thermo Fisher Scientific in the second quarter worth approximately $108,000. Shine Investment Advisory Services Inc. acquired a new stake in Thermo Fisher Scientific in the second quarter worth approximately $113,000. Ropes Wealth Advisors LLC lifted its position in Thermo Fisher Scientific by 15.8% in the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after purchasing an additional 97 shares during the period. Finally, Atlantic Trust LLC acquired a new stake in Thermo Fisher Scientific in the second quarter worth approximately $138,000. Institutional investors and hedge funds own 85.32% of the company’s stock.
Shares of Thermo Fisher Scientific Inc (NYSE:TMO) opened at $192.75 on Thursday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. Thermo Fisher Scientific Inc has a one year low of $139.07 and a one year high of $201.20. The stock has a market cap of $77,364.04, a price-to-earnings ratio of 21.20, a price-to-earnings-growth ratio of 1.77 and a beta of 1.08.
The company also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.31%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.19%.
In other Thermo Fisher Scientific news, VP Seth H. Hoogasian sold 4,140 shares of the business’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $177.80, for a total transaction of $736,092.00. Following the sale, the vice president now directly owns 25,518 shares of the company’s stock, valued at approximately $4,537,100.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Daniel P. Shine sold 2,026 shares of the business’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total transaction of $366,645.22. Following the sale, the insider now directly owns 20,682 shares in the company, valued at $3,742,821.54. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,420 shares of company stock worth $11,308,477. Company insiders own 0.49% of the company’s stock.
A number of equities research analysts have weighed in on TMO shares. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. BidaskClub downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. Cowen and Company reiterated a “buy” rating and set a $200.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, September 1st. Finally, Morgan Stanley reiterated an “overweight” rating and set a $220.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, September 6th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $205.71.
TRADEMARK VIOLATION NOTICE: This story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://sportsperspectives.com/2017/11/23/perennial-advisors-llc-has-2-54-million-stake-in-thermo-fisher-scientific-inc-tmo.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.